Wednesday, November 11, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Third Marketing Agreement For OCU400 Adds Pacific Territories. Ocugen announced a marketing agreement with Celairis Therapeutics Holdings Pty Ltd for commercialization of OCU400 in Australia, New Zealand, Taiwan, and Asian territories known as ASEAN (Association of Southeast Asian Nations). The agreement includes licensing fees, milestones, sales royalties, and a profit split. This is the third OCU400 agreement to add ex-US territories.
New Populations Are Covered. Celairis is a Sydney, Australia-based biopharmaceutical company that licenses, develops, and markets medicines. The licensed territories include Australia, New Zealand, Taiwan, and the ASEAN countries (Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Brunei, Vietnam, Myanmar, Cambodia, and Timor). These new territories add an estimated 725 million people to regions within OCU400’s marketing reach.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
